{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:58:16Z","timestamp":1786121896812,"version":"build-2736575974"},"reference-count":8,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      In the QWINT\u20101 phase 3 Trial, once\u2010weekly insulin efsitora alfa (efsitora) administered using an innovative fixed\u2010dose regimen demonstrated noninferior HbA1c reduction versus once\u2010daily insulin glargine U100 (glargine) over 52\u2009weeks in insulin\u2010na\u00efve adults with type 2 diabetes. This report focuses on baseline characteristics and clinical outcomes of efsitora\u2010treated participants based on their insulin dose at Week 52 (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009303).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Efsitora was dosed using a fixed\u2010dose titration regimen with 100, 150, 250 and 400\u2009U fixed\u2010doses titrated as needed every 4\u2009weeks to achieve fasting blood glucose (FBG) of 80\u2013130\u2009mg\/dL (4.4\u20137.2\u2009mmol\/L). Participants not at target FBG on the 400\u2009U fixed\u2010dose after \u2265\u20094\u2009weeks transitioned to flexible dosing using an efsitora multi\u2010dose pen. Glargine was administered using a multi\u2010dose pen and titrated weekly to the same target. Analyses assessed clinical characteristics and glycaemic outcomes by efsitora dose at Week 52, and hypoglycaemia after fixed\u2010dose increases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants requiring higher Week 52 efsitora doses had greater baseline weight, HbA1c and fasting glucose, and more were male. Most participants (76%) remained on a fixed efsitora dose, and the majority established their final dose by Week 16. All efsitora fixed\u2010doses resulted in robust HbA1c lowering, with mean final HbA1c\u2009&lt;\u20097.0%. Based on events within 4\u2010week periods after an efsitora fixed\u2010dose increase, estimated rates of combined Level 2 and 3 hypoglycaemia were &lt;\u20090.5\u2009events\/year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In QWINT\u20101, the innovative fixed\u2010dose efsitora simple titration resulted in effective HbA1c lowering for all fixed doses. Rates of clinically meaningful hypoglycaemia were low after fixed\u2010dose increases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70814","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:15:47Z","timestamp":1777853747000},"page":"6217-6224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed\u2010Dose Titration of Weekly Insulin Efsitora in Insulin\u2010Na\u00efve Type 2 Diabetes"],"prefix":"10.1111","volume":"28","author":[{"given":"Lisa","family":"Connery","sequence":"first","affiliation":[{"name":"AMR Norman  Norman Oklahoma USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Rasouli","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-606X","authenticated-orcid":false,"given":"Alice Y. Y.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Trillium Health Partners and Unity Health  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Liebl","sequence":"additional","affiliation":[{"name":"m&amp;i\u2010Fachklinik  Bad Heilbrunn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitoria","family":"Pires","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5495-1846","authenticated-orcid":false,"given":"Alastair","family":"Knights","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1235-6990","authenticated-orcid":false,"given":"Michael B.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-2780","authenticated-orcid":false,"given":"Christopher J.","family":"Child","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2019.03.180162"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.17218"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819844694"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15604"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502796"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/jmdh.S64084"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13088"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u20105491.2012.03605.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70814","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:34:27Z","timestamp":1786088067000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/dom.70814"],"URL":"https:\/\/doi.org\/10.1111\/dom.70814","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70814\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70814\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"2025-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}